Evidence map›Paper›PMID 35919207›Full record

ArticleCureus2022

Treatment of Hematomas Using a Synthetic Hybrid-Scale Fiber Matrix.

Eric W Temple

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A debriding gel in the treatment of post-trauma, non-healing lesions.International journal of burns and trauma · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Eric W TempleFoot and Ankle Surgeon, The Iowa Clinic, West Des Moines, USA.
American College of Foot and Ankle Surgeons · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective treatment of traumatic subcutaneous hematomas is important to avoid complications, including skin necrosis, infection, scarring, hyperpigmentation, tissue edema, and prolonged recovery. Hematoma treatment may include evacuation followed by application of a skin substitute. Given the challenges associated with conventional skin substitutes, a fully-synthetic, resorbable, electrospun matrix composed of hybrid-scale fibers may offer a new option for treating hematomas. The present study reports on two clinical case reports assessing the use of the synthetic hybrid-scale fiber matrix for the treatment of hematomas. The hematomas located on the pretibial leg and dorsal foot were debrided in the operating room with evacuation of the hematomas, and the synthetic matrix was applied to the wounds. Following treatment, the wounds were observed for healing progress, including measuring and photographing the wounds and documenting clinical observations. The synthetic hybrid-scale fiber matrix was re-applied as needed based on clinician discretion. In both cases, treatment following the use of the synthetic hybrid-scale fiber matrix resulted in complete healing. Complete closure of all wounds was observed after two to three applications of the synthetic matrix within six to 16 weeks, and no adverse events were noted. In this study, hematomas of the foot and the leg demonstrated successful healing following treatment with the synthetic hybrid-scale fiber matrix. The successful clinical outcomes suggest that this biomaterial may offer benefits as part of a new treatment paradigm for hematomas and warrants further investigation.

Indexed as

hematoma evacuationskin substitutesubcutaneous hematomasynthetic hybrid-scale fiber matrixtrauma­wound healing

Identifiers

PMID35919207
PMCPMC9339210
OpenAlexW4283739255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.